Table I.
Joinpoint regression for DAI indicators, CR-GNB incidence density per 1000 patient-days and antibiotic consumption in DDD per 1000 patient-days in AICU, Paraná, Brazil, 2019–2020
| Variable | Period | MPC | Joinpoint | 95% CI | P-value |
|---|---|---|---|---|---|
| CLABSI/1000 cl-days | Jan 2019–Apr 2019 | –15.5 | 1 | –28.7, 0.1 | 0.051 |
| Apr 2019–Dec 2020 | 1.9 | 1.1, 2.8 | <0.001 | ||
| PAV/1000 mv-days | Jan 2019–Nov 2019 | –1.8 | 1 | –3.2, –0.3 | 0.019 |
| Nov 2019–Dec 2020 | 2.1 | 1.2, 2.9 | <0.001 | ||
| CAUTI/1000 uc-days | Jan 2019–Sep 2019 | –2.8 | 1 | –7.1, 1.7 | 0.209 |
| Sep 2019–Dec 2020 | 1.3 | –0.3, 3.0 | 0.115 | ||
| CRAB/1000 pt-days | Jan 2019–Apr 2020 | 1.1 | 1 | –1.0, 3.4 | 0.286 |
| Apr 2020–Dec 2020 | 14.2 | 10.1, 18.5 | <0.001 | ||
| CRKP/1000 pt-days | Jan 2019–Dec 2020 | 2.4 | 0 | 0.7, 4.1 | 0.008 |
| CRPA/1000 pt-days | Jan 2019–Dec 2020 | 0.5 | 0 | –1.0, 2.1 | 0.478 |
| PMB/1000 pt-days | Jan 2019–Jul 2020 | –1.6 | 1 | –4.2, 1.0 | 0.200 |
| Jul 2020–Dec 2020 | 17.5 | 4.6, 31.9 | 0.009 | ||
| COL/1000 pt-days | Jan 2019–Apr 2020 | –3.1 | 1 | –9.8, 4.0 | 0.362 |
| Apr 2020–Dec 2020 | 30.7 | 17.8, 44.9 | <0.001 | ||
| MEM/1000 pt-days | Jan 2019–Nov 2019 | 1.8 | 2 | 4.5, 1.5 | 0.155 |
| Nov 2019–Aug 2020 | –4.7 | –8.2, –1.0 | 0.015 | ||
| Aug 2020–Dec 2020 | 10.2 | 0.3, 21.1 | 0.043 | ||
| PTZ/1000 pt-days | Jan 2019–Dec 2020 | –0.2 | 0 | –0.8, 0.4 | 0.496 |
| CPM/1000 pt-days | Jan 2019–Dec 2020 | –2.5 | 0 | –3.4, –1.5 | <0.001 |
| CAZ/1000 pt-days | Jan 2019–Nov 2019 | 3.9 | 1 | –0.3, 8.2 | 0.067 |
| Nov 2019–Dec 2020 | –6.4 | –9.1, –3.6 | <0.001 | ||
| CIP/1000 pt-days | Jan 2019–Dec 2020 | –2.5 | 0 | –3.5, –1.5 | <0.001 |
| LVX (P)/1000 pt-days | Jan 2019–Dec 2020 | 2.0 | 0 | 0.1, 3.8 | 0.038 |
| MOX (P)/1000 pt-days | Jan 2019–Dec 2020 | –0.4 | 0 | –2.5, 1.8 | 0.728 |
AICU, adult intensive care unit; CAUTI, catheter-associated urinary tract infection; CAZ (ceftazidime); CIP, ciprofloxacin; cl, central line; CLABSI, central line-associated bloodstream infection; COL, colistin; CPM, cefepime; CRAB, carbapenem-resistant A. baumannii; CR-GNB, carbapenem-resistant Gram-negative bacteria; CRKP, carbapenem-resistant K. pneumoniae; CRPA, carbapenem-resistant P. aeruginosa; DAIs, device-associated infections; DDD, defined daily dose; LVX, levofloxacin; MEM, meropenem; MOX, moxifloxacin; MPC, monthly percent change; mv, mechanical ventilation; (P), parenteral; PMB, polymyxin B; pt, patient; PTZ, piperacillin/tazobactam; uc, urinary catheter; VAP, ventilator-associated pneumonia.